The vesicular stomatitis virus cytopathic effect reduction assay is suitable to quantify polyethylene glycolalpha interferon 2a (PEG-IFN-␣2a) and PEG-IFN-␣2b. Human serum and ribavirin did not interfere with the assay. This bioassay was successfully used for assaying PEG-IFN-␣2a and PEG-IFN-␣2b in serum samples from patients undergoing combination therapy.
The success of any antiviral treatment depends on three groups of factors, those of the host, virus, and drugs (4, 8) . However, patients chronically infected with hepatitis C virus (HCV) with similar viral and host factors and who received the same treatment schedule often exhibit discrepancies in terms of virus eradication (7) . A relationship between variability in drug concentrations in the blood and treatment efficacy has been suggested for ribavirin and alpha interferon (IFN-␣) (1, 5) , but this has not yet been investigated for polyethylene glycol (PEG)-IFN-␣. Such studies require a convenient assay for measuring PEG-IFN-␣ in patient sera.
Detection of IFN-␣ levels in serum can be performed by immunoassay or bioassay (12) . The immunoassay measures the physical quantity of material but does not differentiate between active and inactive molecules. Bioassays for IFN-␣ are based on the protection of cultured cells against the cytopathic effect of a challenge virus (6, 10, 11) .
In this study, we tested the suitability of the vesicular stomatitis virus (VSV) cytopathic effect reduction assay for PEG-IFN-␣ quantification.
The entire procedure of the bioassay was performed with a 96-well microtitration plate. Samples were placed in the first row of wells. Twelve serial twofold dilutions were carried out with Eagle minimal essential medium (MEM) supplemented with 10% fetal bovine serum. An aliquot (0.1 ml) of a suspension of Madin-Darby bovine kidney cells (150,000/ml) was placed in each well. After incubation for 18 h at 37°C, a confluent cell monolayer was obtained. The culture supernatant was drawn off and replaced with a suspension of virus in MEM without fetal bovine serum; 100 50% tissue culture infective doses of VSV was placed in each well in a volume of 0.1 ml. After an additional 24 h of incubation, the cytopathic effects were estimated by visual examination of the monolayers under a microscope. The greatest dilution of sample that still protected the cells was evaluated by comparison with the standard dilution range. The following controls were included in each test: two cell controls, five virus controls (100 50% tissue culture infective doses and dilutions of this viral suspension of 10 Ϫ1 , 10 Ϫ2 , 10 Ϫ3 , and 10 Ϫ4 ). Solutions of PEG-IFN-␣2a (Roche, Neuilly sur Seine, France) or PEG-IFN-␣2b (Schering-Plough, Levallois-Perret, France) in MEM ranging from 0 to 500 IU/ml were assayed as described above. The measured titer correlated well with the solution titer for both PEG-IFN-␣2a (r 2 ϭ 0.99) and PEG-IFN-␣2b (r 2 ϭ 0.99). The dose-response line ( Fig. 1 ) was used as the working standard for the subsequent experiments.
The bioassay detected 5 IU of PEG-IFN-␣ per ml in 95% of the assays. No false positive was observed when assaying a concentration of 0 IU/ml, indicating the high specificity of the test. The reproducibility of the result was verified by repetition of six determinations of five titers (Table 1) .
Human serum from naive patients containing concentrations of PEG-IFN-␣2a or PEG-IFN-␣2b ranging from 0 to 500 IU/ml was assayed. Measured titers and solution titers were highly correlated (PEG-IFN-␣2a, r 2 ϭ 0.97; PEG-IFN␣2b, r 2 ϭ 0.99). The slope of the dose-response line in human serum was not different from that of the working standard (PEG-IFN-␣2a, P ϭ 0.44; PEG-IFN-␣2b, P ϭ 1). Serum samples from 10 normal volunteers and 18 chronic HCV carriers who were not on treatment were assayed; the titer was 0 IU/ml in all cases.
Concentrations of ribavirin (Schering-Plough, Levallois-Perret, France) ranging from 1,000 to 5,000 ng/ml were assayed as were solutions of PEG-IFN-␣. The cell monolayers were al- Human serum containing 3,000 ng of ribavirin per ml and PEG-IFN-␣ titers ranging from 0 to 500 IU/ml were assayed. The measured titers correlated well with solution titers (PEG-IFN-␣2a r 2 ϭ 0.98; PEG-IFN-␣2b r 2 ϭ 0.95). The slopes of the dose-response line in human serum plus ribavirin were similar to those of the working standard (PEG-IFN-␣2a, P ϭ 0,77; PEG-IFN-␣2b, P ϭ 0.31).
Serum samples from 25 patients treated with PEG-IFN-␣2b plus ribavirin and from 9 patients treated with PEG-IFN-␣2a plus ribavirin were assayed. Estimated concentrations in serum ranged from 0 to 125 IU/ml for PEG-IFN-␣2b and from 0 to 190 IU/ml for PEG-IFN-␣2a (Fig. 2) .
The VSV cytopathic effect reduction assay appears to be suitable for quantifying PEG-IFN-␣2a and PEG-IFN-␣2b. Variations can be kept to a minimum by strict standardization of the assay. Controls for cell viability and for the total destruction of the cell monolayer by VSV in the absence of IFN-␣ are included in each plate. Every sample is assayed twice under the same conditions. Hence, our data show good reproducibility of the assay.
Human serum was reported to protect Madin-Darby bovine kidney cells against the cytopathic effect of VSV even without (11) . The similarity of the slope of the dose-response line in serum to that of the working standard confirmed that the inhibition observed was truly due to PEG-IFN-␣. Comparison of the slope of the dose-response line in samples containing ribavirin to that of the working standard also excluded distortion of the test results by ribavirin. HCV-induced endogenous IFN-␣, which would lead to overestimation of the sample titer (9), was not found in the blood of chronic HCV carriers who were not on treatment (1, 2) . Growth or cytotoxic factors in serum were observed in a limited number of cases, but they did not hamper interpretation of the assay.
The VSV cytopathic effect reduction assay was used to quantify the antiviral activities of PEG-IFN-␣2a and PEG-IFN-␣2b in serum samples from patients on combination therapy. The data variability was great for both types of PEG-IFN-␣. The elapsed time from the last dose of PEG-IFN-␣ could be a factor in titer variability, but postdose levels of PEG-IFN-␣ in serum were reported to be essentially flat for most subjects (3) . Discrepancies in PEG-IFN-␣ titers in serum could also be attributed to interindividual variability in PEG-IFN-␣ pharmacokinetics.
This study shows that the VSV cytopathic effect reduction assay is suitable for assaying PEG-IFN-␣2a and PEG-IFN-␣2b. The concentration of PEG-IFN-␣ in serum samples from patients on combination therapy can be measured with this bioassay.
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